Objective To investigate the effect of bicalutamide combined with goserelin on the expressions of Raptor and SMYD3 in tumor tissue of patients with advanced prostate cancer.Methods A total of 58 patients with advanced prostate cancer were randomly divided into control group and observation group, 29 cases in each group.The control group was treated with bicalutamide and continuous administration of goserelin, while the observation group was treated with the same dose of bicalutamide and intermittent administration of goserelin.The pain relief rate, quality of life and the incidence rate of adverse reactions were analyzed.Raptor protein and SMYD3 expressions were detected in both groups.Results The pain relief rate was 82.76% in the observation group, which was significantly higher than 37.93% in the control group (P=0.000).After treatment, the prostate specific antigen (PSA) decreased significantly in both groups (P=0.000).After treatment, the Raptor staining intensity and SMYD3 expression rate were significantly lower in the observation group than the control group (P=0.000).The score of SF-36 in the observation group was significantly higher than that in the control group, and the incidence rate of adverse reactions in the observation group was significantly lower than that in the control group (P=0.000).Conclusion Bicalutamide combined with goserelin can effectively control Raptor protein and SMYD3 expression in patients withadvanced prostate cancer, and the intermittent administration of drugs has a better therapeutic effect and higher safety.%目的 探讨比卡鲁胺联合戈舍瑞林对晚期前列腺癌患者肿瘤组织中Raptor蛋白及SMYD3表达的影响.方法 选取晚期前列腺癌患者共58例,随机分为对照组和观察组各29例,对照组使用比卡鲁胺联合戈舍瑞林持续给药,观察组使用相同药物和剂量间歇给药.比较2组患者的疼痛缓解率、生活质量、不良反应发生率,检测2组患者前列腺特异性抗原(PSA)、Raptor蛋白及SMYD3表达.结果 观察组疼痛缓解率为82.76%, 显著高于对照组37.93%(P=0.000);治疗后2组患者的PSA均显著下降(P=0.000);治疗后2组患者的Raptor蛋白染色强度和SMYD3表达阳性率均显著低于治疗前,且观察组均显著低于对照组(P=0.000);治疗后观察组的生活质量评价量表(SF-36)分数均显著高于对照组,不良反发生率显著低于对照组(P=0.000).结论 比卡鲁胺联合戈舍瑞林可有效控制晚期前列腺癌患者Raptor蛋白及SMYD3表达,并且间歇给药方法具有更好的治疗效果和更高的安全性.
展开▼
